Skip to content
Clinical Trials – home

Centre Hospitalier Regional Et Universitaire De Brest

Verified siteinfo

France 5 Avenue Marechal Foch, Bp 824, 29609 Brest, France

  • 255 trials recruiting
  • Non-small cell lung cancer · Gastric cancer · Sjogren's syndrome
  • Adults and children

About Specializations

Centre Hospitalier Regional Et Universitaire De Brest in Brest, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Gastric cancer, Sjogren's syndrome, Oesophageal adenocarcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms Research

At Centre Hospitalier Regional Et Universitaire De Brest, clinical research in oncology is focused on improving care for people with Triple Negative Breast Cancer, especially those with residual disease after initial treatment. The studies are designed to better understand whether adding or adjusting treatment after surgery can improve outcomes for patients with this aggressive cancer type.

  • Evaluating new treatment strategies for Triple Negative Breast Cancer
  • Assessing the benefit of additional therapy after surgery in patients with residual disease
  • Studying ways to improve invasive disease-free survival and long-term cancer control

This work reflects a strong focus on cancer treatment effectiveness and post-operative care within the hospital’s Institut de cancérologie et d'hématologie.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
5 Avenue Marechal Foch, Bp 82429609 BrestFrance
Recruiting now
255 trials
Conditions studied
337
Partner status
Verified site

More sites in BrestFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

550 clinical trials

Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Asthma

Recruiting

A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Astrazeneca AB

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.